PEAK6
RNAM

PEAK6’s Avidity Biosciences RNAM Stock Holding History

PEAK6’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,500
Closed -$218K – 3530
2024
Q4 		$218K Buy
+7,500
New +$313K ﹤0.01% 2512

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PEAK6's RNAM Position: Q1 2025 in Review

PEAK6 sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 7,500 shares — an estimated $218K sold.

PEAK6 first reported a position in RNAM in Q4 2024 and held it in 1 quarter. The position peaked at $218K in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • PEAK6 reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • PEAK6 sold 7,500 Avidity Biosciences shares in Q1 2025, an estimated $218K.
  • PEAK6 first reported a position in Avidity Biosciences in Q4 2024 and held it in 1 quarter.
  • PEAK6's Avidity Biosciences position peaked at $218K in Q4 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.